• Explore /
  • Poster
  • / A biomarker-directed phase 2 trial of SY-1425, a selective retinoic acid receptor alpha agonist, in adult patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

A biomarker-directed phase 2 trial of SY-1425, a selective retinoic acid receptor alpha agonist, in adult patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Abstract Poster

Authors

null

Rachel J. Cook

Oregon Health & Science University, Portland, OR

Rachel J. Cook , Eytan Stein , David P. Steensma , Mikkael A. Sekeres , Dale L. Bixby , David Rizzieri , Joseph G. Jurcic , Carlos Enrique Vigil , Robert Redner , Gail J. Roboz , Michael R. Savona , Michael R. McKeown , Kristin Stephens , David A. Roth , Jorge E. Cortes

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Sub Track

Acute Leukemia

Clinical Trial Registration Number

NCT02807558

Citation

J Clin Oncol 35, 2017 (suppl; abstr TPS7071)

DOI

10.1200/JCO.2017.35.15_suppl.TPS7071

Abstract #

TPS7071

Poster Bd #

268b

Abstract Disclosures

Similar Posters

First Author: Amy Elizabeth Dezern

First Author: Guillermo Garcia-Manero

First Author: Curtis Andrew Lachowiez

First Author: Uwe Platzbecker